Senate Committee Turns 340B Spotlight on Drugmakers

340B

Lawmakers turned their sharp scrutiny of the 340B program on drugmakers Tuesday, questioning why states and providers don’t know the ceiling prices within the drug discount program. In a hearing Tuesday, members of the Senate health committee asked government watchdogs why the Trump administration has delayed for the fifth time a rule that would set…

Federal Watchdogs Urge More Oversight of Drug Discount Program

340B

Officials from two federal watchdogs told a Senate committee Tuesday that a drug discount program for hospitals needs additional transparency and oversight to effectively monitor participants. The so-called 340B program, which allows safety net hospitals access to discounted drugs for providing uncompensated care, has become a flashpoint between drug manufacturers that claim providers drive up prices by…